Bill SponsorBILLSPONSOR
Bill Sponsor
Politicians
Bills
Senate Bill 3105
115th Congress(2017-2018)
Pharmaceutical Origin Transparency Act of 2018
Introduced
Introduced
Introduced in Senate on Jun 21, 2018
Overview
Text
Introduced in Senate 
Jun 21, 2018
Not Scanned for Linkage
About Linkage
Multiple bills can contain the same text. This could be an identical bill in the opposite chamber or a smaller bill with a section embedded in a larger bill.
Bill Sponsor regularly scans bill texts to find sections that are contained in other bill texts. When a matching section is found, the bills containing that section can be viewed by clicking "View Bills" within the bill text section.
Bill Sponsor is currently only finding exact word-for-word section matches. In a future release, partial matches will be included.
Introduced in Senate(Jun 21, 2018)
Jun 21, 2018
Not Scanned for Linkage
About Linkage
Multiple bills can contain the same text. This could be an identical bill in the opposite chamber or a smaller bill with a section embedded in a larger bill.
Bill Sponsor regularly scans bill texts to find sections that are contained in other bill texts. When a matching section is found, the bills containing that section can be viewed by clicking "View Bills" within the bill text section.
Bill Sponsor is currently only finding exact word-for-word section matches. In a future release, partial matches will be included.
Jump To
S. 3105 (Introduced-in-Senate)


115th CONGRESS
2d Session
S. 3105


To require manufacturers of drugs to post the names of the countries in which their drugs are manufactured on their internet websites.

IN THE SENATE OF THE UNITED STATES

June 21, 2018

Mrs. McCaskill introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions

A BILL

To require manufacturers of drugs to post the names of the countries in which their drugs are manufactured on their internet websites.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. Short title.

This Act may be cited as the “Pharmaceutical Origin Transparency Act of 2018”.

SEC. 2. Information about drug manufacturing.

Section 301 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331) is amended by adding at the end the following:

“(eee) (1) The introduction or delivery for introduction into interstate commerce of any drug subject to section 503(b)(1), unless the manufacturer of such drug maintains on its internet website information about each country in which such drug is manufactured.

“(2) For purposes of this paragraph, a drug is manufactured in a country if the active pharmaceutical ingredient is manufactured in such country.”.